Mesa Laboratories Inc (MLAB) KPIs and segments
Close on Nov 12, 2026Market cap $756.56MP/E 117.6Yield 0.47%
KPIs & segments
Operating metrics and segments that drive Mesa Laboratories's business
Mesa Laboratories's revenue by segment, product and region, plus the counts and sizes it tags in its 10-K and 10-Q filings (XBRL). Each figure links to the filing it came from. A fuller KPI sheet built from earnings releases and presentations is on the way. See the segment tables for a trailing-twelve-month view, or how companies compare on operating metrics.
The chart is empty. Tick the box next to any metric in the table below to plot it — tick several to compare them on one chart.
Mesa Laboratories's fiscal year ends March 31 — Q1 FY27 = CQ2 2026 (calendar quarter).
| Add to chart | Metric | Q1 FY27 CQ2 2026 | Q4 FY26 CQ1 2026 | Q3 FY26 CQ4 2025 | Q2 FY26 CQ3 2025 | Q1 FY26 CQ2 2025 | Q4 FY25 CQ1 2025 | Q3 FY25 CQ4 2024 | Q2 FY25 CQ3 2024 | Q1 FY25 CQ2 2024 | Q4 FY24 CQ1 2024 | Q3 FY24 CQ4 2023 | Q2 FY24 CQ3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sterilization and Disinfection Control($M) | 24.5 | 29.1 | 24.9 | 22.1 | 25.4 | 24.7 | 23.5 | 22.2 | 23.0 | 22.8 | 19.3 | 17.1 | |
Calibration Solutions($M) | 13.3 | 13.6 | 14.1 | 13.6 | 12.4 | 13.3 | 14.4 | 12.3 | 11.8 | 12.8 | 12.2 | 11.3 | |
Biopharmaceutical Development($M) | 12.1 | 8.85 | 14.4 | 13.9 | 11.5 | 12.6 | 12.2 | 11.9 | 12.0 | 12.2 | 9.43 | 9.21 | |
Clinical Genomics($M) | 10.3 | 12.2 | 11.8 | 11.1 | 10.3 | 11.5 | 12.7 | 11.5 | 11.4 | 11.1 | 12.5 | 15.5 | |
Product($M) | 19.6 | 62.8 | 57.8 | 58.2 | 19.5 | 53.5 | 53.2 | ||||||
United States($M) | 29.7 | 30.1 | 29.9 | 29.3 | 27.6 | 31.2 | 30.5 | 28.1 | 26.9 | 27.2 | 25.6 | 27.1 | |
Other($M) | 25.0 | 29.6 | 29.6 | 26.1 | 26.5 | 25.9 | 26.0 | 22.4 | 24.8 | 25.4 | 22.9 | 18.6 | |
China($M) | 5.44 | 4.06 | 5.65 | 5.32 | 5.43 | 5.04 | 6.32 | 7.39 | 6.56 | 6.35 | 4.94 | 7.53 | |
Sterilization and Disinfection Control($M) | 17.2 | 21.4 | 17.3 | 14.9 | 18.2 | 17.5 | 16.5 | 15.2 | 15.6 | 15.3 | 14.0 | 12.5 | |
Calibration Solutions($M) | 8.03 | 8.26 | 8.45 | 8.24 | 7.04 | 7.38 | 8.81 | 7.21 | 7.24 | 7.50 | 7.21 | 6.41 | |
Biopharmaceutical Development($M) | 7.58 | 5.20 | 8.92 | 8.13 | 6.31 | 7.25 | 7.54 | 7.17 | 7.96 | 7.62 | 5.84 | 5.51 | |
Clinical Genomics($M) | 6.24 | 7.39 | 7.11 | 6.10 | 5.43 | 6.33 | 6.95 | 5.91 | 6.49 | 6.17 | 6.45 | 7.73 | |
30 metrics have no data in the last 12 quarters — .
Italic numbers are calculated by StockData from reported figures (hover for the formula). Numbers with a dotted underline are read from the text of earnings releases and presentations; hover to see the exact sentence. Tick a row to add it to the chart above (up to 8 lines).
Methodology and excluded metrics
- Core rows come from the segment and revenue-disaggregation notes of 10-K and 10-Q filings (XBRL), linked to each filing. Fourth-quarter figures are the fiscal year less the first nine months (shown in italic).
Data updated 2026-08-10.
See a number that looks wrong?